1
|
Ineveld RL, Margaritis T, Kooiman BA, Groenveld F, Ariese HC, Lijnzaad P, Johnson HR, Korving J, Wehrens EJ, Holstege F, Rheenen J, Drost J, Rios AC, Bos FL. Cover Image. Dev Dyn 2021. [DOI: 10.1002/dvdy.432] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
2
|
van Ineveld RL, Kleinnijenhuis M, Alieva M, de Blank S, Barrera Roman M, van Vliet EJ, Martínez Mir C, Johnson HR, Bos FL, Heukers R, Chuva de Sousa Lopes SM, Drost J, Dekkers JF, Wehrens EJ, Rios AC. Revealing the spatio-phenotypic patterning of cells in healthy and tumor tissues with mLSR-3D and STAPL-3D. Nat Biotechnol 2021; 39:1239-1245. [PMID: 34083793 PMCID: PMC7611791 DOI: 10.1038/s41587-021-00926-3] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/11/2020] [Accepted: 04/16/2021] [Indexed: 12/12/2022]
Abstract
Despite advances in three-dimensional (3D) imaging, it remains challenging to profile all the cells within a large 3D tissue, including the morphology and organization of the many cell types present. Here, we introduce eight-color, multispectral, large-scale single-cell resolution 3D (mLSR-3D) imaging and image analysis software for the parallelized, deep learning-based segmentation of large numbers of single cells in tissues, called segmentation analysis by parallelization of 3D datasets (STAPL-3D). Applying the method to pediatric Wilms tumor, we extract molecular, spatial and morphological features of millions of cells and reconstruct the tumor’s spatio-phenotypic patterning. In situ population profiling and pseudotime ordering reveals a highly disorganized spatial pattern in Wilms tumor compared to healthy fetal kidney, yet cellular profiles closely resembling human fetal kidney cells could be observed. In addition, we identify previously unreported tumor-specific populations, uniquely characterized by their spatial embedding or morphological attributes. Our results demonstrate the use of combining mLSR-3D and STAPL-3D to generate a comprehensive cellular map of human tumors.
Collapse
Affiliation(s)
- Ravian L van Ineveld
- Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.,Cancer Genomics Netherlands, Oncode Institute, Utrecht, the Netherlands
| | - Michiel Kleinnijenhuis
- Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.,Cancer Genomics Netherlands, Oncode Institute, Utrecht, the Netherlands
| | - Maria Alieva
- Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.,Cancer Genomics Netherlands, Oncode Institute, Utrecht, the Netherlands
| | - Sam de Blank
- Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.,Cancer Genomics Netherlands, Oncode Institute, Utrecht, the Netherlands
| | - Mario Barrera Roman
- Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.,Cancer Genomics Netherlands, Oncode Institute, Utrecht, the Netherlands
| | - Esmée J van Vliet
- Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.,Cancer Genomics Netherlands, Oncode Institute, Utrecht, the Netherlands
| | - Clara Martínez Mir
- Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.,Cancer Genomics Netherlands, Oncode Institute, Utrecht, the Netherlands
| | - Hannah R Johnson
- Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.,Cancer Genomics Netherlands, Oncode Institute, Utrecht, the Netherlands
| | - Frank L Bos
- Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.,Cancer Genomics Netherlands, Oncode Institute, Utrecht, the Netherlands
| | | | | | - Jarno Drost
- Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.,Cancer Genomics Netherlands, Oncode Institute, Utrecht, the Netherlands
| | - Johanna F Dekkers
- Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.,Cancer Genomics Netherlands, Oncode Institute, Utrecht, the Netherlands
| | - Ellen J Wehrens
- Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.,Cancer Genomics Netherlands, Oncode Institute, Utrecht, the Netherlands
| | - Anne C Rios
- Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands. .,Cancer Genomics Netherlands, Oncode Institute, Utrecht, the Netherlands.
| |
Collapse
|
3
|
van Ineveld RL, Margaritis T, Kooiman BAP, Groenveld F, Ariese HCR, Lijnzaad P, Johnson HR, Korving J, Wehrens EJ, Holstege F, van Rheenen J, Drost J, Rios AC, Bos FL. LGR6 marks nephron progenitor cells. Dev Dyn 2021; 250:1568-1583. [PMID: 33848015 PMCID: PMC8597161 DOI: 10.1002/dvdy.346] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2020] [Revised: 02/05/2021] [Accepted: 02/07/2021] [Indexed: 11/12/2022] Open
Abstract
Background Nephron progenitor cells (NPCs) undergo a stepwise process to generate all mature nephron structures. Mesenchymal to epithelial transition (MET) is considered a multistep process of NPC differentiation to ensure progressive establishment of new nephrons. However, despite this important role, to date, no marker for NPCs undergoing MET in the nephron exists. Results Here, we identify LGR6 as a NPC marker, expressed in very early cap mesenchyme, pre‐tubular aggregates, renal vesicles, and in segments of S‐shaped bodies, following the trajectory of MET. By using a lineage tracing approach in embryonic explants in combination with confocal imaging and single‐cell RNA sequencing, we provide evidence for the multiple fates of LGR6+ cells during embryonic nephrogenesis. Moreover, by using long‐term in vivo lineage tracing, we show that postnatal LGR6+ cells are capable of generating the multiple lineages of the nephrons. Conclusions Given the profound early mesenchymal expression and MET signature of LGR6+ cells, together with the lineage tracing of mesenchymal LGR6+ cells, we conclude that LGR6+ cells contribute to all nephrogenic segments by undergoing MET. LGR6+ cells can therefore be considered an early committed NPC population during embryonic and postnatal nephrogenesis with potential regenerative capability. Lgr6 is expressed in the earliest cap mesenchyme pool, a niche where nephrogenic progenitor cells (NPCs) are found. Lgr6 marks NPCs undergoing mesenchymal to epithelial transition, following the main process of nephron development. Using ex vivo and vivo lineage tracing, we show that mesenchymal Lgr6 expressing cells give rise to multiple types of mesenchymal derived nephron segments, including specialized glomerular epithelium, such as podocytes.
Collapse
Affiliation(s)
- Ravian L van Ineveld
- Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.,Oncode Institute, Utrecht, The Netherlands
| | | | | | - Femke Groenveld
- Hubrecht Institute, Royal Netherlands Academy of Arts and Sciences (KNAW) and University Medical Center (UMC) Utrecht, Utrecht, The Netherlands
| | - Hendrikus C R Ariese
- Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.,Oncode Institute, Utrecht, The Netherlands
| | - Philip Lijnzaad
- Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands
| | - Hannah R Johnson
- Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.,Oncode Institute, Utrecht, The Netherlands
| | - Jeroen Korving
- Hubrecht Institute, Royal Netherlands Academy of Arts and Sciences (KNAW) and University Medical Center (UMC) Utrecht, Utrecht, The Netherlands
| | - Ellen J Wehrens
- Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.,Oncode Institute, Utrecht, The Netherlands
| | - Frank Holstege
- Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands
| | - Jacco van Rheenen
- Oncode Institute, Utrecht, The Netherlands.,Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
| | - Jarno Drost
- Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.,Oncode Institute, Utrecht, The Netherlands
| | - Anne C Rios
- Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.,Oncode Institute, Utrecht, The Netherlands
| | - Frank L Bos
- Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.,Oncode Institute, Utrecht, The Netherlands
| |
Collapse
|
4
|
Wander P, Arentsen-Peters STCJM, Pinhanҫos SS, Koopmans B, Dolman MEM, Ariese R, Bos FL, Castro PG, Jones L, Schneider P, Navarro MG, Molenaar JJ, Rios AC, Zwaan CM, Stam RW. High-throughput drug screening reveals Pyrvinium pamoate as effective candidate against pediatric MLL-rearranged acute myeloid leukemia. Transl Oncol 2021; 14:101048. [PMID: 33667892 PMCID: PMC7933809 DOI: 10.1016/j.tranon.2021.101048] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2021] [Revised: 02/12/2021] [Accepted: 02/17/2021] [Indexed: 12/27/2022] Open
Abstract
Drug library screening identified pyrvinium to be effective against MLL-rearranged AML. Pyrvinium targets the mitochondria of MLL-rearranged AML cells. Pyrvinium does not antagonize with standard chemotherapy in MLL-rearranged AML.
Pediatric MLL-rearranged acute myeloid leukemia (AML) has a generally unfavorable outcome, primarily due to relapse and drug resistance. To overcome these difficulties, new therapeutic agents are urgently needed. Yet, implementing novel drugs for clinical use is a time-consuming, laborious, costly and high-risk process. Therefore, we applied a drug-repositioning strategy by screening drug libraries, comprised of >4000 compounds that are mostly FDA-approved, in a high-throughput format on primary MLL-rearranged AML cells. Here we identified pyrvinium pamoate (pyrvinium) as a novel candidate drug effective against MLL-rearranged AML, eliminating all cell viability at <1000 nM. Additional screening of identified drug hits on non-leukemic bone marrow samples, resulted in a decrease in cell viability of ∼50% at 1000 nM pyrvinium, suggesting a therapeutic window for targeting leukemic cells specifically. Validation of pyrvinium on an extensive panel of AML cell lines and primary AML samples showed comparable viabilities as the drug screen data, with pyrvinium achieving IC50 values of <80 nM in these samples. Remarkably, pyrvinium also induced cell toxicity in primary MLL-AF10+ AML cells, an MLL-rearrangement associated with a poor outcome. While pyrvinium is able to inhibit the Wnt pathway in other diseases, this unlikely explains the efficacy we observed as β-catenin was not expressed in the AML cells tested. Rather, we show that pyrvinium co-localized with the mitochondrial stain in cells, and hence may act by inhibiting mitochondrial respiration. Overall, this study shows that pyrvinium is highly effective against MLL-rearranged AML in vitro, and therefore represents a novel potential candidate for further studies in MLL-rearranged AML.
Collapse
Affiliation(s)
- Priscilla Wander
- Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584CS Utrecht, Netherlands; Department of Pediatric Oncology/Hematology, Erasmus MC-Sophia Children's Hospital, Rotterdam, Netherlands
| | | | - Sandra S Pinhanҫos
- Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584CS Utrecht, Netherlands; CNC-Center for Neurosciences and Cell Biology, University of Coimbra, Coimbra, Portugal
| | - Bianca Koopmans
- Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584CS Utrecht, Netherlands
| | - M Emmy M Dolman
- Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584CS Utrecht, Netherlands
| | - Rijndert Ariese
- Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584CS Utrecht, Netherlands; Oncode Institute, Utrecht, Netherlands
| | - Frank L Bos
- Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584CS Utrecht, Netherlands; Oncode Institute, Utrecht, Netherlands
| | - Patricia Garrido Castro
- Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584CS Utrecht, Netherlands
| | - Luke Jones
- Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584CS Utrecht, Netherlands
| | - Pauline Schneider
- Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584CS Utrecht, Netherlands
| | - Miriam Guillen Navarro
- Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584CS Utrecht, Netherlands
| | - Jan J Molenaar
- Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584CS Utrecht, Netherlands
| | - Anne C Rios
- Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584CS Utrecht, Netherlands; Oncode Institute, Utrecht, Netherlands
| | - C Michel Zwaan
- Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584CS Utrecht, Netherlands; Department of Pediatric Oncology/Hematology, Erasmus MC-Sophia Children's Hospital, Rotterdam, Netherlands
| | - Ronald W Stam
- Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584CS Utrecht, Netherlands.
| |
Collapse
|
5
|
Hanemaaijer ES, Margaritis T, Sanders K, Bos FL, Candelli T, Al-Saati H, van Noesel MM, Meyer-Wentrup FAG, van de Wetering M, Holstege FCP, Clevers H. Single-cell atlas of developing murine adrenal gland reveals relation of Schwann cell precursor signature to neuroblastoma phenotype. Proc Natl Acad Sci U S A 2021; 118:e2022350118. [PMID: 33500353 PMCID: PMC7865168 DOI: 10.1073/pnas.2022350118] [Citation(s) in RCA: 37] [Impact Index Per Article: 12.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
Neuroblastoma is the most common extracranial solid tumor and accounts for ∼10% of pediatric cancer-related deaths. The exact cell of origin has yet to be elucidated, but it is generally accepted that neuroblastoma derives from the neural crest and should thus be considered an embryonal malignancy. About 50% of primary neuroblastoma tumors arise in the adrenal gland. Here, we present an atlas of the developing mouse adrenal gland at a single-cell level. Five main cell cluster groups (medulla, cortex, endothelial, stroma, and immune) make up the mouse adrenal gland during fetal development. The medulla group, which is of neural crest origin, is further divided into seven clusters. Of interest is the Schwann cell precursor ("SCP") and the "neuroblast" cluster, a highly cycling cluster that shares markers with sympathoblasts. The signature of the medullary SCP cluster differentiates neuroblastoma patients based on disease phenotype: The SCP signature score anticorrelates with ALK and MYCN expression, two indicators of poor prognosis. Furthermore, a high SCP signature score is associated with better overall survival rates. This study provides an insight into the developing adrenal gland and introduces the SCP gene signature as being of interest for further research in understanding neuroblastoma phenotype.
Collapse
Affiliation(s)
- Evelyn S Hanemaaijer
- Oncode Institute, Princess Máxima Center for Pediatric Oncology, 3584 CS Utrecht, The Netherlands
| | - Thanasis Margaritis
- Princess Máxima Center for Pediatric Oncology, 3584 CS Utrecht, The Netherlands
| | - Karin Sanders
- Oncode Institute, Princess Máxima Center for Pediatric Oncology, 3584 CS Utrecht, The Netherlands
- Department of Clinical Sciences, Faculty of Veterinary Medicine, Utrecht University, 3584 CM Utrecht, The Netherlands
| | - Frank L Bos
- Oncode Institute, Princess Máxima Center for Pediatric Oncology, 3584 CS Utrecht, The Netherlands
| | - Tito Candelli
- Princess Máxima Center for Pediatric Oncology, 3584 CS Utrecht, The Netherlands
| | - Hanin Al-Saati
- Oncode Institute, Princess Máxima Center for Pediatric Oncology, 3584 CS Utrecht, The Netherlands
| | - Max M van Noesel
- Princess Máxima Center for Pediatric Oncology, 3584 CS Utrecht, The Netherlands
| | | | - Marc van de Wetering
- Oncode Institute, Princess Máxima Center for Pediatric Oncology, 3584 CS Utrecht, The Netherlands
| | - Frank C P Holstege
- Princess Máxima Center for Pediatric Oncology, 3584 CS Utrecht, The Netherlands
| | - Hans Clevers
- Oncode Institute, Princess Máxima Center for Pediatric Oncology, 3584 CS Utrecht, The Netherlands;
- Oncode Institute, Hubrecht Institute, Royal Netherlands Academy of Arts and Sciences and University Medical Center, 3584 CT Utrecht, The Netherlands
| |
Collapse
|
6
|
Pichol-Thievend C, Betterman KL, Liu X, Ma W, Skoczylas R, Lesieur E, Bos FL, Schulte D, Schulte-Merker S, Hogan BM, Oliver G, Harvey NL, Francois M. A blood capillary plexus-derived population of progenitor cells contributes to genesis of the dermal lymphatic vasculature during embryonic development. Development 2018; 145:145/10/dev160184. [PMID: 29773646 DOI: 10.1242/dev.160184] [Citation(s) in RCA: 47] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2017] [Accepted: 04/20/2018] [Indexed: 01/04/2023]
Abstract
Despite the essential role of the lymphatic vasculature in tissue homeostasis and disease, knowledge of the organ-specific origins of lymphatic endothelial progenitor cells remains limited. The assumption that most murine embryonic lymphatic endothelial cells (LECs) are venous derived has recently been challenged. Here, we show that the embryonic dermal blood capillary plexus constitutes an additional, local source of LECs that contributes to the formation of the dermal lymphatic vascular network. We describe a novel mechanism whereby rare PROX1-positive endothelial cells exit the capillary plexus in a Ccbe1-dependent manner to establish discrete LEC clusters. As development proceeds, these clusters expand and further contribute to the growing lymphatic system. Lineage tracing and analyses of Gata2-deficient mice confirmed that these clusters are endothelial in origin. Furthermore, ectopic expression of Vegfc in the vasculature increased the number of PROX1-positive progenitors within the capillary bed. Our work reveals a novel source of lymphatic endothelial progenitors employed during construction of the dermal lymphatic vasculature and demonstrates that the blood vasculature is likely to remain an ongoing source of LECs during organogenesis, raising the question of whether a similar mechanism operates during pathological lymphangiogenesis.
Collapse
Affiliation(s)
- Cathy Pichol-Thievend
- Institute for Molecular Bioscience, The University of Queensland, Brisbane, QLD 4072, Australia
| | - Kelly L Betterman
- Centre for Cancer Biology, University of South Australia and SA Pathology, Adelaide 5001, South Australia, Australia
| | - Xiaolei Liu
- Center for Vascular and Developmental Biology, Feinberg Cardiovascular Research Institute, Northwestern University, Chicago, IL 60611, USA
| | - Wanshu Ma
- Center for Vascular and Developmental Biology, Feinberg Cardiovascular Research Institute, Northwestern University, Chicago, IL 60611, USA
| | - Renae Skoczylas
- Institute for Molecular Bioscience, The University of Queensland, Brisbane, QLD 4072, Australia
| | - Emmanuelle Lesieur
- Institute for Molecular Bioscience, The University of Queensland, Brisbane, QLD 4072, Australia
| | - Frank L Bos
- Hubrecht Institute, Royal Netherlands Academy of Arts and Sciences (KNAW) and University Medical Centre, Utrecht 3584CT, The Netherlands
| | - Dorte Schulte
- University of Münster, 48149 Münster, Germany Institute for Cardiovascular Organogenesis and Regeneration, Faculty of Medicine, Westfälische Wilhelms-Universität Münster (WWU), Mendelstrasse 7, 48149 Münster and CiM Cluster of Excellence, Germany
| | - Stefan Schulte-Merker
- University of Münster, 48149 Münster, Germany Institute for Cardiovascular Organogenesis and Regeneration, Faculty of Medicine, Westfälische Wilhelms-Universität Münster (WWU), Mendelstrasse 7, 48149 Münster and CiM Cluster of Excellence, Germany
| | - Benjamin M Hogan
- Institute for Molecular Bioscience, The University of Queensland, Brisbane, QLD 4072, Australia
| | - Guillermo Oliver
- Center for Vascular and Developmental Biology, Feinberg Cardiovascular Research Institute, Northwestern University, Chicago, IL 60611, USA
| | - Natasha L Harvey
- Centre for Cancer Biology, University of South Australia and SA Pathology, Adelaide 5001, South Australia, Australia
| | - Mathias Francois
- Institute for Molecular Bioscience, The University of Queensland, Brisbane, QLD 4072, Australia
| |
Collapse
|
7
|
Campbell F, Bos FL, Sieber S, Arias-Alpizar G, Koch BE, Huwyler J, Kros A, Bussmann J. Directing Nanoparticle Biodistribution through Evasion and Exploitation of Stab2-Dependent Nanoparticle Uptake. ACS Nano 2018; 12:2138-2150. [PMID: 29320626 PMCID: PMC5876619 DOI: 10.1021/acsnano.7b06995] [Citation(s) in RCA: 144] [Impact Index Per Article: 24.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/17/2023]
Abstract
Up to 99% of systemically administered nanoparticles are cleared through the liver. Within the liver, most nanoparticles are thought to be sequestered by macrophages (Kupffer cells), although significant nanoparticle interactions with other hepatic cells have also been observed. To achieve effective cell-specific targeting of drugs through nanoparticle encapsulation, improved mechanistic understanding of nanoparticle-liver interactions is required. Here, we show the caudal vein of the embryonic zebrafish ( Danio rerio) can be used as a model for assessing nanoparticle interactions with mammalian liver sinusoidal (or scavenger) endothelial cells (SECs) and macrophages. We observe that anionic nanoparticles are primarily taken up by SECs and identify an essential requirement for the scavenger receptor, stabilin-2 ( stab2) in this process. Importantly, nanoparticle-SEC interactions can be blocked by dextran sulfate, a competitive inhibitor of stab2 and other scavenger receptors. Finally, we exploit nanoparticle-SEC interactions to demonstrate targeted intracellular drug delivery resulting in the selective deletion of a single blood vessel in the zebrafish embryo. Together, we propose stab2 inhibition or targeting as a general approach for modifying nanoparticle-liver interactions of a wide range of nanomedicines.
Collapse
Affiliation(s)
- Frederick Campbell
- Department
of Supramolecular and Biomaterials Chemistry, Leiden Institute of Chemistry (LIC), Leiden University, P.O. Box 9502, 2300 RA Leiden, The Netherlands
- E-mail:
| | - Frank L. Bos
- Hubrecht-Institute-KNAW
and University Medical Centre and Centre for Biomedical Genetics, Uppsalalaan 8, 3584 CT Utrecht, The Netherlands
| | - Sandro Sieber
- Division
of Pharmaceutical Technology, Department of Pharmaceutical Science, University of Basel, Klingelbergstrasse 50, Basel CH-4056, Switzerland
| | - Gabriela Arias-Alpizar
- Department
of Supramolecular and Biomaterials Chemistry, Leiden Institute of Chemistry (LIC), Leiden University, P.O. Box 9502, 2300 RA Leiden, The Netherlands
| | - Bjørn E. Koch
- Department
of Molecular Cell Biology, Institute Biology
Leiden (IBL), Leiden University, P.O.
Box 9502, 2300 RA Leiden, The Netherlands
| | - Jörg Huwyler
- Division
of Pharmaceutical Technology, Department of Pharmaceutical Science, University of Basel, Klingelbergstrasse 50, Basel CH-4056, Switzerland
| | - Alexander Kros
- Department
of Supramolecular and Biomaterials Chemistry, Leiden Institute of Chemistry (LIC), Leiden University, P.O. Box 9502, 2300 RA Leiden, The Netherlands
- E-mail:
| | - Jeroen Bussmann
- Department
of Supramolecular and Biomaterials Chemistry, Leiden Institute of Chemistry (LIC), Leiden University, P.O. Box 9502, 2300 RA Leiden, The Netherlands
- Department
of Molecular Cell Biology, Institute Biology
Leiden (IBL), Leiden University, P.O.
Box 9502, 2300 RA Leiden, The Netherlands
- E-mail:
| |
Collapse
|
8
|
Ponder KL, Bárcena A, Bos FL, Gormley M, Zhou Y, Ona K, Kapidzic M, Zovein AC, Fisher SJ. Preeclampsia and Inflammatory Preterm Labor Alter the Human Placental Hematopoietic Niche. Reprod Sci 2016; 23:1179-92. [PMID: 26944948 DOI: 10.1177/1933719116632926] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
BACKGROUND The human placenta is a source of hematopoietic stem and progenitor cells (HSPCs). The RUNX1 transcription factor is required for the formation of functional HSPCs. The impact of preeclampsia (PE) and preterm labor (PTL, spontaneous preterm labor [sPTL] and inflammatory preterm labor [iPTL]) on HSPC localization and RUNX1 expression in the human placenta is unknown. METHODS We compared the frequency and density of HSPC in control samples from sPTL (n = 6) versus PE (n = 6) and iPTL (n = 6). We examined RUNX1 protein and RNA expression in placentas from normal pregnancies (5-22 weeks, n = 8 total) and in placentas from the aforementioned pregnancy complications (n = 5/group). RESULTS Hematopoietic stem and progenitor cells were rare cell types, associated predominantly with the vasculature of placental villi. The HSPC density was greater in the chorionic plate (CP) compared to the villi (P < .001) and greater in PE and iPTL samples as compared to controls within the CP (not significant) and overall (P < .05). During the fetal period, RUNX1 was expressed in the mesenchyme of the CP and villi. Inflammatory PTL samples were more likely to exhibit intraluminal RUNX1(+) cell populations (P < .001) and RUNX1(+) cell clusters attached to arterial endothelial cells. CONCLUSION Placental HSPCs likely arise from hematopoietic niches comprised RUNX1(+) mesenchyme and vascular endothelium. Pregnancy complications that result in preterm birth differentially affect placental HSPC localization and RUNX1 expression. Our results support previous findings that inflammation positively regulates hematopoiesis. We present new evidence that hemogenic endothelium may be active at later stages of human fetal development in the context of inflammation.
Collapse
Affiliation(s)
- Kathryn L Ponder
- Division of Neonatology, Department of Pediatrics, University of California San Francisco, San Francisco, CA, USA
| | - Alicia Bárcena
- Department of Obstetrics, Gynecology and Reproductive Sciences, Center for Reproductive Sciences, Eli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research, University of California San Francisco, San Francisco, CA, USA
| | - Frank L Bos
- Cardiovascular Research Institute, University of California San Francisco, San Francisco, CA, USA
| | - Matthew Gormley
- Department of Obstetrics, Gynecology and Reproductive Sciences, Center for Reproductive Sciences, Eli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research, University of California San Francisco, San Francisco, CA, USA
| | - Yan Zhou
- Department of Obstetrics, Gynecology and Reproductive Sciences, Center for Reproductive Sciences, Eli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research, University of California San Francisco, San Francisco, CA, USA
| | - Katherine Ona
- Department of Obstetrics, Gynecology and Reproductive Sciences, Center for Reproductive Sciences, Eli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research, University of California San Francisco, San Francisco, CA, USA
| | - Mirhan Kapidzic
- Department of Obstetrics, Gynecology and Reproductive Sciences, Center for Reproductive Sciences, Eli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research, University of California San Francisco, San Francisco, CA, USA
| | - Ann C Zovein
- Division of Neonatology, Department of Pediatrics, University of California San Francisco, San Francisco, CA, USA Cardiovascular Research Institute, University of California San Francisco, San Francisco, CA, USA
| | - Susan J Fisher
- Department of Obstetrics, Gynecology and Reproductive Sciences, Center for Reproductive Sciences, Eli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research, University of California San Francisco, San Francisco, CA, USA
| |
Collapse
|
9
|
Haasdijk RA, Den Dekker WK, Cheng C, Tempel D, Szulcek R, Bos FL, Hermkens DMA, Chrifi I, Brandt MM, Van Dijk C, Xu YJ, Van De Kamp EHM, Blonden LAJ, Van Bezu J, Sluimer JC, Biessen EAL, Van Nieuw Amerongen GP, Duckers HJ. THSD1 preserves vascular integrity and protects against intraplaque haemorrhaging in ApoE-/- mice. Cardiovasc Res 2016; 110:129-39. [PMID: 26822228 DOI: 10.1093/cvr/cvw015] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/16/2015] [Accepted: 01/07/2016] [Indexed: 12/15/2022] Open
Abstract
AIMS Impairment of the endothelial barrier leads to microvascular breakdown in cardiovascular disease and is involved in intraplaque haemorrhaging and the progression of advanced atherosclerotic lesions that are vulnerable to rupture. The exact mechanism that regulates vascular integrity requires further definition. Using a microarray screen for angiogenesis-associated genes during murine embryogenesis, we identified thrombospondin type I domain 1 (THSD1) as a new putative angiopotent factor with unknown biological function. We sought to characterize the role of THSD1 in endothelial cells during vascular development and cardiovascular disease. METHODS AND RESULTS Functional knockdown of Thsd1 in zebrafish embryos and in a murine retina vascularization model induced severe haemorrhaging without affecting neovascular growth. In human carotid endarterectomy specimens, THSD1 expression by endothelial cells was detected in advanced atherosclerotic lesions with intraplaque haemorrhaging, but was absent in stable lesions, implying involvement of THSD1 in neovascular bleeding. In vitro, stimulation with pro-atherogenic factors (3% O2 and TNFα) decreased THSD1 expression in human endothelial cells, whereas stimulation with an anti-atherogenic factor (IL10) showed opposite effect. Therapeutic evaluation in a murine advanced atherosclerosis model showed that Thsd1 overexpression decreased plaque vulnerability by attenuating intraplaque vascular leakage, subsequently reducing macrophage accumulation and necrotic core size. Mechanistic studies in human endothelial cells demonstrated that THSD1 activates FAK-PI3K, leading to Rac1-mediated actin cytoskeleton regulation of adherens junctions and focal adhesion assembly. CONCLUSION THSD1 is a new regulator of endothelial barrier function during vascular development and protects intraplaque microvessels against haemorrhaging in advanced atherosclerotic lesions.
Collapse
Affiliation(s)
- Remco A Haasdijk
- Department of Cardiology, Erasmus Medical Center Rotterdam, Rotterdam, The Netherlands
| | - Wijnand K Den Dekker
- Department of Cardiology, Erasmus Medical Center Rotterdam, Rotterdam, The Netherlands
| | - Caroline Cheng
- Department of Cardiology, Erasmus Medical Center Rotterdam, Rotterdam, The Netherlands Regenerative Vascular Medicine Laboratory, Department of Nephrology and Hypertension, Division of Internal Medicine and Dermatology, University Medical Center Utrecht, Heidelberglaan 100, PO Box 85500, 3584 CX Utrecht, 3508 GA Utrecht, The Netherlands
| | - Dennie Tempel
- Department of Cardiology, University Medical Center Utrecht, Utrecht, The Netherlands
| | - Robert Szulcek
- Department of Physiology, Institute for Cardiovascular Research, VU University Medical Center Amsterdam, Amsterdam, The Netherlands
| | - Frank L Bos
- Department of Cardiology, Erasmus Medical Center Rotterdam, Rotterdam, The Netherlands Hubrecht Institute, Utrecht, The Netherlands
| | - Dorien M A Hermkens
- Department of Cardiology, Erasmus Medical Center Rotterdam, Rotterdam, The Netherlands Hubrecht Institute, Utrecht, The Netherlands
| | - Ihsan Chrifi
- Department of Cardiology, Erasmus Medical Center Rotterdam, Rotterdam, The Netherlands Regenerative Vascular Medicine Laboratory, Department of Nephrology and Hypertension, Division of Internal Medicine and Dermatology, University Medical Center Utrecht, Heidelberglaan 100, PO Box 85500, 3584 CX Utrecht, 3508 GA Utrecht, The Netherlands
| | - Maarten M Brandt
- Department of Cardiology, Erasmus Medical Center Rotterdam, Rotterdam, The Netherlands Regenerative Vascular Medicine Laboratory, Department of Nephrology and Hypertension, Division of Internal Medicine and Dermatology, University Medical Center Utrecht, Heidelberglaan 100, PO Box 85500, 3584 CX Utrecht, 3508 GA Utrecht, The Netherlands
| | - Chris Van Dijk
- Regenerative Vascular Medicine Laboratory, Department of Nephrology and Hypertension, Division of Internal Medicine and Dermatology, University Medical Center Utrecht, Heidelberglaan 100, PO Box 85500, 3584 CX Utrecht, 3508 GA Utrecht, The Netherlands
| | - Yan Juan Xu
- Regenerative Vascular Medicine Laboratory, Department of Nephrology and Hypertension, Division of Internal Medicine and Dermatology, University Medical Center Utrecht, Heidelberglaan 100, PO Box 85500, 3584 CX Utrecht, 3508 GA Utrecht, The Netherlands
| | | | - Lau A J Blonden
- Department of Cardiology, Erasmus Medical Center Rotterdam, Rotterdam, The Netherlands
| | - Jan Van Bezu
- Department of Physiology, Institute for Cardiovascular Research, VU University Medical Center Amsterdam, Amsterdam, The Netherlands
| | - Judith C Sluimer
- Department of Pathology, Maastricht University Medical Center, Maastricht, The Netherlands
| | - Erik A L Biessen
- Department of Pathology, Maastricht University Medical Center, Maastricht, The Netherlands
| | - Geerten P Van Nieuw Amerongen
- Department of Physiology, Institute for Cardiovascular Research, VU University Medical Center Amsterdam, Amsterdam, The Netherlands
| | - Henricus J Duckers
- Department of Cardiology, University Medical Center Utrecht, Utrecht, The Netherlands
| |
Collapse
|
10
|
Abstract
Endothelial-to-hematopoietic transition (EHT) occurs within a population of hemogenic endothelial cells during embryogenesis, and leads to the formation of the adult hematopoietic system. Currently, the prospective identification of specific endothelial cells that will undergo EHT, and the cellular events enabling this transition, are not known. We set out to define precisely the morphological events of EHT, and to correlate cellular morphology with the expression of the transcription factors RUNX1 and SOX17. A novel strategy was developed to allow for correlation of immunofluorescence data with the ultrastructural resolution of scanning electron microscopy. The approach can identify single endothelial cells undergoing EHT, as identified by the ratio of RUNX1 to SOX17 immunofluorescence levels, and the morphological changes associated with the transition. Furthermore, this work details a new technical resource that is widely applicable for correlative analyses of single cells in their native tissue environments.
Collapse
Affiliation(s)
- Frank L Bos
- Cardiovascular Research Institute, University of California San Francisco, San Francisco, CA 94158, USA
| | - John S Hawkins
- Cardiovascular Research Institute, University of California San Francisco, San Francisco, CA 94158, USA
| | - Ann C Zovein
- Cardiovascular Research Institute, University of California San Francisco, San Francisco, CA 94158, USA Department of Pediatrics, Division of Neonatology, University of California San Francisco School of Medicine, San Francisco, CA 94143, USA
| |
Collapse
|
11
|
Roukens MG, Peterson-Maduro J, Padberg Y, Jeltsch M, Leppänen VM, Bos FL, Alitalo K, Schulte-Merker S, Schulte D. Functional Dissection of the CCBE1 Protein. Circ Res 2015; 116:1660-9. [DOI: 10.1161/circresaha.116.304949] [Citation(s) in RCA: 34] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/31/2014] [Accepted: 03/26/2015] [Indexed: 01/15/2023]
Affiliation(s)
- M. Guy Roukens
- From the Hubrecht Institute, KNAW–UMC Utrecht, Utrecht, The Netherlands (M.G.R., J.P.M., Y.P., F.L.B., S.S.-M., D.S.); Cardiovascular Research Institute, University of California San Francisco (F.L.B.); Translational Cancer Biology Program, University of Helsinki, Biomedicum Helsinki, Helsinki, Finland (M.J., V.-M. L., K.A.); Wihuri Research Institute, Biomedicum Helsinki, Helsinki, Finland (M.J., V.-M. L., K.A.); Institute for Cardiovascular Organogenesis and Regeneration, Faculty of Medicine, WWU,
| | - Josi Peterson-Maduro
- From the Hubrecht Institute, KNAW–UMC Utrecht, Utrecht, The Netherlands (M.G.R., J.P.M., Y.P., F.L.B., S.S.-M., D.S.); Cardiovascular Research Institute, University of California San Francisco (F.L.B.); Translational Cancer Biology Program, University of Helsinki, Biomedicum Helsinki, Helsinki, Finland (M.J., V.-M. L., K.A.); Wihuri Research Institute, Biomedicum Helsinki, Helsinki, Finland (M.J., V.-M. L., K.A.); Institute for Cardiovascular Organogenesis and Regeneration, Faculty of Medicine, WWU,
| | - Yvonne Padberg
- From the Hubrecht Institute, KNAW–UMC Utrecht, Utrecht, The Netherlands (M.G.R., J.P.M., Y.P., F.L.B., S.S.-M., D.S.); Cardiovascular Research Institute, University of California San Francisco (F.L.B.); Translational Cancer Biology Program, University of Helsinki, Biomedicum Helsinki, Helsinki, Finland (M.J., V.-M. L., K.A.); Wihuri Research Institute, Biomedicum Helsinki, Helsinki, Finland (M.J., V.-M. L., K.A.); Institute for Cardiovascular Organogenesis and Regeneration, Faculty of Medicine, WWU,
| | - Michael Jeltsch
- From the Hubrecht Institute, KNAW–UMC Utrecht, Utrecht, The Netherlands (M.G.R., J.P.M., Y.P., F.L.B., S.S.-M., D.S.); Cardiovascular Research Institute, University of California San Francisco (F.L.B.); Translational Cancer Biology Program, University of Helsinki, Biomedicum Helsinki, Helsinki, Finland (M.J., V.-M. L., K.A.); Wihuri Research Institute, Biomedicum Helsinki, Helsinki, Finland (M.J., V.-M. L., K.A.); Institute for Cardiovascular Organogenesis and Regeneration, Faculty of Medicine, WWU,
| | - Veli-Matti Leppänen
- From the Hubrecht Institute, KNAW–UMC Utrecht, Utrecht, The Netherlands (M.G.R., J.P.M., Y.P., F.L.B., S.S.-M., D.S.); Cardiovascular Research Institute, University of California San Francisco (F.L.B.); Translational Cancer Biology Program, University of Helsinki, Biomedicum Helsinki, Helsinki, Finland (M.J., V.-M. L., K.A.); Wihuri Research Institute, Biomedicum Helsinki, Helsinki, Finland (M.J., V.-M. L., K.A.); Institute for Cardiovascular Organogenesis and Regeneration, Faculty of Medicine, WWU,
| | - Frank L. Bos
- From the Hubrecht Institute, KNAW–UMC Utrecht, Utrecht, The Netherlands (M.G.R., J.P.M., Y.P., F.L.B., S.S.-M., D.S.); Cardiovascular Research Institute, University of California San Francisco (F.L.B.); Translational Cancer Biology Program, University of Helsinki, Biomedicum Helsinki, Helsinki, Finland (M.J., V.-M. L., K.A.); Wihuri Research Institute, Biomedicum Helsinki, Helsinki, Finland (M.J., V.-M. L., K.A.); Institute for Cardiovascular Organogenesis and Regeneration, Faculty of Medicine, WWU,
| | - Kari Alitalo
- From the Hubrecht Institute, KNAW–UMC Utrecht, Utrecht, The Netherlands (M.G.R., J.P.M., Y.P., F.L.B., S.S.-M., D.S.); Cardiovascular Research Institute, University of California San Francisco (F.L.B.); Translational Cancer Biology Program, University of Helsinki, Biomedicum Helsinki, Helsinki, Finland (M.J., V.-M. L., K.A.); Wihuri Research Institute, Biomedicum Helsinki, Helsinki, Finland (M.J., V.-M. L., K.A.); Institute for Cardiovascular Organogenesis and Regeneration, Faculty of Medicine, WWU,
| | - Stefan Schulte-Merker
- From the Hubrecht Institute, KNAW–UMC Utrecht, Utrecht, The Netherlands (M.G.R., J.P.M., Y.P., F.L.B., S.S.-M., D.S.); Cardiovascular Research Institute, University of California San Francisco (F.L.B.); Translational Cancer Biology Program, University of Helsinki, Biomedicum Helsinki, Helsinki, Finland (M.J., V.-M. L., K.A.); Wihuri Research Institute, Biomedicum Helsinki, Helsinki, Finland (M.J., V.-M. L., K.A.); Institute for Cardiovascular Organogenesis and Regeneration, Faculty of Medicine, WWU,
| | - Dörte Schulte
- From the Hubrecht Institute, KNAW–UMC Utrecht, Utrecht, The Netherlands (M.G.R., J.P.M., Y.P., F.L.B., S.S.-M., D.S.); Cardiovascular Research Institute, University of California San Francisco (F.L.B.); Translational Cancer Biology Program, University of Helsinki, Biomedicum Helsinki, Helsinki, Finland (M.J., V.-M. L., K.A.); Wihuri Research Institute, Biomedicum Helsinki, Helsinki, Finland (M.J., V.-M. L., K.A.); Institute for Cardiovascular Organogenesis and Regeneration, Faculty of Medicine, WWU,
| |
Collapse
|
12
|
Bos FL, Caunt M, Peterson-Maduro J, Planas-Paz L, Kowalski J, Karpanen T, van Impel A, Tong R, Ernst JA, Korving J, van Es JH, Lammert E, Duckers HJ, Schulte-Merker S. CCBE1 Is Essential for Mammalian Lymphatic Vascular Development and Enhances the Lymphangiogenic Effect of Vascular Endothelial Growth Factor-C In Vivo. Circ Res 2011; 109:486-91. [DOI: 10.1161/circresaha.111.250738] [Citation(s) in RCA: 155] [Impact Index Per Article: 11.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Rationale:
Collagen- and calcium-binding EGF domains 1 (CCBE1) has been associated with Hennekam syndrome, in which patients have lymphedema, lymphangiectasias, and other cardiovascular anomalies. Insight into the molecular role of CCBE1 is completely lacking, and mouse models for the disease do not exist.
Objective:
CCBE1 deficient mice were generated to understand the function of CCBE1 in cardiovascular development, and CCBE1 recombinant protein was used in both in vivo and in vitro settings to gain insight into the molecular function of CCBE1.
Methods and Results:
Phenotypic analysis of murine
Ccbe1
mutant embryos showed a complete lack of definitive lymphatic structures, even though Prox1
+
lymphatic endothelial cells get specified within the cardinal vein. Mutant mice die prenatally. Proximity ligation assays indicate that vascular endothelial growth factor receptor 3 activation appears unaltered in mutants. Human CCBE1 protein binds to components of the extracellular matrix in vitro, and CCBE1 protein strongly enhances vascular endothelial growth factor-C–mediated lymphangiogenesis in a corneal micropocket assay.
Conclusions:
Our data identify CCBE1 as a factor critically required for budding and migration of Prox-1
+
lymphatic endothelial cells from the cardinal vein. CCBE1 probably exerts these effects through binding to components of the extracellular matrix. CCBE1 has little lymphangiogenic effect on its own but dramatically enhances the lymphangiogenic effect of vascular endothelial growth factor-C in vivo. Thus, our data suggest CCBE1 to be essential but not sufficient for lymphangiogenesis.
Collapse
Affiliation(s)
- Frank L. Bos
- From the Hubrecht Institute-KNAW and UMC Utrecht, Utrecht, The Netherlands (F.L.B., J.P.-M., T.K., A.v.I., J.K., J.H.v.E., S.S.-M.); EMC, Rotterdam, The Netherlands (F.L.B., H.J.D.); the Molecular Biology Department, Genentech Inc, South San Francisco, CA (M.C., J.K.); the Institute of Metabolic Physiology, Heinrich Heine Universität Düsseldorf, Düsseldorf, Germany (L.P.-P., E.L.); the Protein Chemistry Department, Genentech Inc, South San Francisco, CA (R.T., J.A.E.); and EZO Department, University
| | - Maresa Caunt
- From the Hubrecht Institute-KNAW and UMC Utrecht, Utrecht, The Netherlands (F.L.B., J.P.-M., T.K., A.v.I., J.K., J.H.v.E., S.S.-M.); EMC, Rotterdam, The Netherlands (F.L.B., H.J.D.); the Molecular Biology Department, Genentech Inc, South San Francisco, CA (M.C., J.K.); the Institute of Metabolic Physiology, Heinrich Heine Universität Düsseldorf, Düsseldorf, Germany (L.P.-P., E.L.); the Protein Chemistry Department, Genentech Inc, South San Francisco, CA (R.T., J.A.E.); and EZO Department, University
| | - Josi Peterson-Maduro
- From the Hubrecht Institute-KNAW and UMC Utrecht, Utrecht, The Netherlands (F.L.B., J.P.-M., T.K., A.v.I., J.K., J.H.v.E., S.S.-M.); EMC, Rotterdam, The Netherlands (F.L.B., H.J.D.); the Molecular Biology Department, Genentech Inc, South San Francisco, CA (M.C., J.K.); the Institute of Metabolic Physiology, Heinrich Heine Universität Düsseldorf, Düsseldorf, Germany (L.P.-P., E.L.); the Protein Chemistry Department, Genentech Inc, South San Francisco, CA (R.T., J.A.E.); and EZO Department, University
| | - Lara Planas-Paz
- From the Hubrecht Institute-KNAW and UMC Utrecht, Utrecht, The Netherlands (F.L.B., J.P.-M., T.K., A.v.I., J.K., J.H.v.E., S.S.-M.); EMC, Rotterdam, The Netherlands (F.L.B., H.J.D.); the Molecular Biology Department, Genentech Inc, South San Francisco, CA (M.C., J.K.); the Institute of Metabolic Physiology, Heinrich Heine Universität Düsseldorf, Düsseldorf, Germany (L.P.-P., E.L.); the Protein Chemistry Department, Genentech Inc, South San Francisco, CA (R.T., J.A.E.); and EZO Department, University
| | - Joe Kowalski
- From the Hubrecht Institute-KNAW and UMC Utrecht, Utrecht, The Netherlands (F.L.B., J.P.-M., T.K., A.v.I., J.K., J.H.v.E., S.S.-M.); EMC, Rotterdam, The Netherlands (F.L.B., H.J.D.); the Molecular Biology Department, Genentech Inc, South San Francisco, CA (M.C., J.K.); the Institute of Metabolic Physiology, Heinrich Heine Universität Düsseldorf, Düsseldorf, Germany (L.P.-P., E.L.); the Protein Chemistry Department, Genentech Inc, South San Francisco, CA (R.T., J.A.E.); and EZO Department, University
| | - Terhi Karpanen
- From the Hubrecht Institute-KNAW and UMC Utrecht, Utrecht, The Netherlands (F.L.B., J.P.-M., T.K., A.v.I., J.K., J.H.v.E., S.S.-M.); EMC, Rotterdam, The Netherlands (F.L.B., H.J.D.); the Molecular Biology Department, Genentech Inc, South San Francisco, CA (M.C., J.K.); the Institute of Metabolic Physiology, Heinrich Heine Universität Düsseldorf, Düsseldorf, Germany (L.P.-P., E.L.); the Protein Chemistry Department, Genentech Inc, South San Francisco, CA (R.T., J.A.E.); and EZO Department, University
| | - Andreas van Impel
- From the Hubrecht Institute-KNAW and UMC Utrecht, Utrecht, The Netherlands (F.L.B., J.P.-M., T.K., A.v.I., J.K., J.H.v.E., S.S.-M.); EMC, Rotterdam, The Netherlands (F.L.B., H.J.D.); the Molecular Biology Department, Genentech Inc, South San Francisco, CA (M.C., J.K.); the Institute of Metabolic Physiology, Heinrich Heine Universität Düsseldorf, Düsseldorf, Germany (L.P.-P., E.L.); the Protein Chemistry Department, Genentech Inc, South San Francisco, CA (R.T., J.A.E.); and EZO Department, University
| | - Raymond Tong
- From the Hubrecht Institute-KNAW and UMC Utrecht, Utrecht, The Netherlands (F.L.B., J.P.-M., T.K., A.v.I., J.K., J.H.v.E., S.S.-M.); EMC, Rotterdam, The Netherlands (F.L.B., H.J.D.); the Molecular Biology Department, Genentech Inc, South San Francisco, CA (M.C., J.K.); the Institute of Metabolic Physiology, Heinrich Heine Universität Düsseldorf, Düsseldorf, Germany (L.P.-P., E.L.); the Protein Chemistry Department, Genentech Inc, South San Francisco, CA (R.T., J.A.E.); and EZO Department, University
| | - James A. Ernst
- From the Hubrecht Institute-KNAW and UMC Utrecht, Utrecht, The Netherlands (F.L.B., J.P.-M., T.K., A.v.I., J.K., J.H.v.E., S.S.-M.); EMC, Rotterdam, The Netherlands (F.L.B., H.J.D.); the Molecular Biology Department, Genentech Inc, South San Francisco, CA (M.C., J.K.); the Institute of Metabolic Physiology, Heinrich Heine Universität Düsseldorf, Düsseldorf, Germany (L.P.-P., E.L.); the Protein Chemistry Department, Genentech Inc, South San Francisco, CA (R.T., J.A.E.); and EZO Department, University
| | - Jeroen Korving
- From the Hubrecht Institute-KNAW and UMC Utrecht, Utrecht, The Netherlands (F.L.B., J.P.-M., T.K., A.v.I., J.K., J.H.v.E., S.S.-M.); EMC, Rotterdam, The Netherlands (F.L.B., H.J.D.); the Molecular Biology Department, Genentech Inc, South San Francisco, CA (M.C., J.K.); the Institute of Metabolic Physiology, Heinrich Heine Universität Düsseldorf, Düsseldorf, Germany (L.P.-P., E.L.); the Protein Chemistry Department, Genentech Inc, South San Francisco, CA (R.T., J.A.E.); and EZO Department, University
| | - Johan H. van Es
- From the Hubrecht Institute-KNAW and UMC Utrecht, Utrecht, The Netherlands (F.L.B., J.P.-M., T.K., A.v.I., J.K., J.H.v.E., S.S.-M.); EMC, Rotterdam, The Netherlands (F.L.B., H.J.D.); the Molecular Biology Department, Genentech Inc, South San Francisco, CA (M.C., J.K.); the Institute of Metabolic Physiology, Heinrich Heine Universität Düsseldorf, Düsseldorf, Germany (L.P.-P., E.L.); the Protein Chemistry Department, Genentech Inc, South San Francisco, CA (R.T., J.A.E.); and EZO Department, University
| | - Eckhard Lammert
- From the Hubrecht Institute-KNAW and UMC Utrecht, Utrecht, The Netherlands (F.L.B., J.P.-M., T.K., A.v.I., J.K., J.H.v.E., S.S.-M.); EMC, Rotterdam, The Netherlands (F.L.B., H.J.D.); the Molecular Biology Department, Genentech Inc, South San Francisco, CA (M.C., J.K.); the Institute of Metabolic Physiology, Heinrich Heine Universität Düsseldorf, Düsseldorf, Germany (L.P.-P., E.L.); the Protein Chemistry Department, Genentech Inc, South San Francisco, CA (R.T., J.A.E.); and EZO Department, University
| | - Henricus J. Duckers
- From the Hubrecht Institute-KNAW and UMC Utrecht, Utrecht, The Netherlands (F.L.B., J.P.-M., T.K., A.v.I., J.K., J.H.v.E., S.S.-M.); EMC, Rotterdam, The Netherlands (F.L.B., H.J.D.); the Molecular Biology Department, Genentech Inc, South San Francisco, CA (M.C., J.K.); the Institute of Metabolic Physiology, Heinrich Heine Universität Düsseldorf, Düsseldorf, Germany (L.P.-P., E.L.); the Protein Chemistry Department, Genentech Inc, South San Francisco, CA (R.T., J.A.E.); and EZO Department, University
| | - Stefan Schulte-Merker
- From the Hubrecht Institute-KNAW and UMC Utrecht, Utrecht, The Netherlands (F.L.B., J.P.-M., T.K., A.v.I., J.K., J.H.v.E., S.S.-M.); EMC, Rotterdam, The Netherlands (F.L.B., H.J.D.); the Molecular Biology Department, Genentech Inc, South San Francisco, CA (M.C., J.K.); the Institute of Metabolic Physiology, Heinrich Heine Universität Düsseldorf, Düsseldorf, Germany (L.P.-P., E.L.); the Protein Chemistry Department, Genentech Inc, South San Francisco, CA (R.T., J.A.E.); and EZO Department, University
| |
Collapse
|
13
|
Cheng C, Tempel D, Den Dekker WK, Haasdijk R, Chrifi I, Bos FL, Wagtmans K, van de Kamp EH, Blonden L, Biessen EA, Moll F, Pasterkamp G, Serruys PW, Schulte-Merker S, Duckers HJ. Ets2 Determines the Inflammatory State of Endothelial Cells in Advanced Atherosclerotic Lesions. Circ Res 2011; 109:382-95. [DOI: 10.1161/circresaha.111.243444] [Citation(s) in RCA: 34] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
Rationale:
Neovascularization is required for embryonic development and plays a central role in diseases in adults. In atherosclerosis, the role of neovascularization remains to be elucidated. In a genome-wide microarray-screen of Flk1+ angioblasts during murine embryogenesis, the v-ets erythroblastosis virus E26 oncogene homolog 2 (Ets2) transcription factor was identified as a potential angiogenic factor.
Objectives:
We assessed the role of Ets2 in endothelial cells during atherosclerotic lesion progression toward plaque instability.
Methods and Results:
In 91 patients treated for carotid artery disease, Ets2 levels showed modest correlations with capillary growth, thrombogenicity, and rising levels of tumor necrosis factor-α (TNFα), monocyte chemoattractant protein 1, and interleukin-6 in the atherosclerotic lesions. Experiments in ApoE
−/−
mice, using a vulnerable plaque model, showed that Ets2 expression was increased under atherogenic conditions and was augmented specifically in the vulnerable versus stable lesions. In endothelial cell cultures, Ets2 expression and activation was responsive to the atherogenic cytokine TNFα. In the murine vulnerable plaque model, overexpression of Ets2 promoted lesion growth with neovessel formation, hemorrhaging, and plaque destabilization. In contrast, Ets2 silencing, using a lentiviral shRNA construct, promoted lesion stabilization. In vitro studies showed that Ets2 was crucial for TNFα-induced expression of monocyte chemoattractant protein 1, interleukin-6, and vascular cell adhesion molecule 1 in endothelial cells. In addition, Ets2 promoted tube formation and amplified TNFα-induced loss of vascular endothelial integrity. Evaluation in a murine retina model further validated the role of Ets2 in regulating vessel inflammation and endothelial leakage.
Conclusions:
We provide the first evidence for the plaque-destabilizing role of Ets2 in atherosclerosis development by induction of an intraplaque proinflammatory phenotype in endothelial cells.
Collapse
Affiliation(s)
- Caroline Cheng
- From the Molecular Cardiology Laboratory, Experimental Cardiology, Thoraxcenter, Erasmus University Medical Center, Rotterdam, The Netherlands (C.C., D.T., W.K.D.D., R.H., I.C., F.L.B., K.W., E.v.d.K., L.B., P.W.S., H.J.D.); Hubrecht's Institute-KNAW and University Medical Centre, Utrecht, The Netherlands (F.L.B., S.S.-M.); the Department of Pathology, Maastricht University Medical Center, Maastricht, The Netherlands (E.A.L.B.); and the Departments of Vascular Surgery (F.M.) and Cardiology (G.P.),
| | - Dennie Tempel
- From the Molecular Cardiology Laboratory, Experimental Cardiology, Thoraxcenter, Erasmus University Medical Center, Rotterdam, The Netherlands (C.C., D.T., W.K.D.D., R.H., I.C., F.L.B., K.W., E.v.d.K., L.B., P.W.S., H.J.D.); Hubrecht's Institute-KNAW and University Medical Centre, Utrecht, The Netherlands (F.L.B., S.S.-M.); the Department of Pathology, Maastricht University Medical Center, Maastricht, The Netherlands (E.A.L.B.); and the Departments of Vascular Surgery (F.M.) and Cardiology (G.P.),
| | - Wijnand K. Den Dekker
- From the Molecular Cardiology Laboratory, Experimental Cardiology, Thoraxcenter, Erasmus University Medical Center, Rotterdam, The Netherlands (C.C., D.T., W.K.D.D., R.H., I.C., F.L.B., K.W., E.v.d.K., L.B., P.W.S., H.J.D.); Hubrecht's Institute-KNAW and University Medical Centre, Utrecht, The Netherlands (F.L.B., S.S.-M.); the Department of Pathology, Maastricht University Medical Center, Maastricht, The Netherlands (E.A.L.B.); and the Departments of Vascular Surgery (F.M.) and Cardiology (G.P.),
| | - Remco Haasdijk
- From the Molecular Cardiology Laboratory, Experimental Cardiology, Thoraxcenter, Erasmus University Medical Center, Rotterdam, The Netherlands (C.C., D.T., W.K.D.D., R.H., I.C., F.L.B., K.W., E.v.d.K., L.B., P.W.S., H.J.D.); Hubrecht's Institute-KNAW and University Medical Centre, Utrecht, The Netherlands (F.L.B., S.S.-M.); the Department of Pathology, Maastricht University Medical Center, Maastricht, The Netherlands (E.A.L.B.); and the Departments of Vascular Surgery (F.M.) and Cardiology (G.P.),
| | - Ihsan Chrifi
- From the Molecular Cardiology Laboratory, Experimental Cardiology, Thoraxcenter, Erasmus University Medical Center, Rotterdam, The Netherlands (C.C., D.T., W.K.D.D., R.H., I.C., F.L.B., K.W., E.v.d.K., L.B., P.W.S., H.J.D.); Hubrecht's Institute-KNAW and University Medical Centre, Utrecht, The Netherlands (F.L.B., S.S.-M.); the Department of Pathology, Maastricht University Medical Center, Maastricht, The Netherlands (E.A.L.B.); and the Departments of Vascular Surgery (F.M.) and Cardiology (G.P.),
| | - Frank L. Bos
- From the Molecular Cardiology Laboratory, Experimental Cardiology, Thoraxcenter, Erasmus University Medical Center, Rotterdam, The Netherlands (C.C., D.T., W.K.D.D., R.H., I.C., F.L.B., K.W., E.v.d.K., L.B., P.W.S., H.J.D.); Hubrecht's Institute-KNAW and University Medical Centre, Utrecht, The Netherlands (F.L.B., S.S.-M.); the Department of Pathology, Maastricht University Medical Center, Maastricht, The Netherlands (E.A.L.B.); and the Departments of Vascular Surgery (F.M.) and Cardiology (G.P.),
| | - Kim Wagtmans
- From the Molecular Cardiology Laboratory, Experimental Cardiology, Thoraxcenter, Erasmus University Medical Center, Rotterdam, The Netherlands (C.C., D.T., W.K.D.D., R.H., I.C., F.L.B., K.W., E.v.d.K., L.B., P.W.S., H.J.D.); Hubrecht's Institute-KNAW and University Medical Centre, Utrecht, The Netherlands (F.L.B., S.S.-M.); the Department of Pathology, Maastricht University Medical Center, Maastricht, The Netherlands (E.A.L.B.); and the Departments of Vascular Surgery (F.M.) and Cardiology (G.P.),
| | - Esther H. van de Kamp
- From the Molecular Cardiology Laboratory, Experimental Cardiology, Thoraxcenter, Erasmus University Medical Center, Rotterdam, The Netherlands (C.C., D.T., W.K.D.D., R.H., I.C., F.L.B., K.W., E.v.d.K., L.B., P.W.S., H.J.D.); Hubrecht's Institute-KNAW and University Medical Centre, Utrecht, The Netherlands (F.L.B., S.S.-M.); the Department of Pathology, Maastricht University Medical Center, Maastricht, The Netherlands (E.A.L.B.); and the Departments of Vascular Surgery (F.M.) and Cardiology (G.P.),
| | - Lau Blonden
- From the Molecular Cardiology Laboratory, Experimental Cardiology, Thoraxcenter, Erasmus University Medical Center, Rotterdam, The Netherlands (C.C., D.T., W.K.D.D., R.H., I.C., F.L.B., K.W., E.v.d.K., L.B., P.W.S., H.J.D.); Hubrecht's Institute-KNAW and University Medical Centre, Utrecht, The Netherlands (F.L.B., S.S.-M.); the Department of Pathology, Maastricht University Medical Center, Maastricht, The Netherlands (E.A.L.B.); and the Departments of Vascular Surgery (F.M.) and Cardiology (G.P.),
| | - Erik A.L. Biessen
- From the Molecular Cardiology Laboratory, Experimental Cardiology, Thoraxcenter, Erasmus University Medical Center, Rotterdam, The Netherlands (C.C., D.T., W.K.D.D., R.H., I.C., F.L.B., K.W., E.v.d.K., L.B., P.W.S., H.J.D.); Hubrecht's Institute-KNAW and University Medical Centre, Utrecht, The Netherlands (F.L.B., S.S.-M.); the Department of Pathology, Maastricht University Medical Center, Maastricht, The Netherlands (E.A.L.B.); and the Departments of Vascular Surgery (F.M.) and Cardiology (G.P.),
| | - Frans Moll
- From the Molecular Cardiology Laboratory, Experimental Cardiology, Thoraxcenter, Erasmus University Medical Center, Rotterdam, The Netherlands (C.C., D.T., W.K.D.D., R.H., I.C., F.L.B., K.W., E.v.d.K., L.B., P.W.S., H.J.D.); Hubrecht's Institute-KNAW and University Medical Centre, Utrecht, The Netherlands (F.L.B., S.S.-M.); the Department of Pathology, Maastricht University Medical Center, Maastricht, The Netherlands (E.A.L.B.); and the Departments of Vascular Surgery (F.M.) and Cardiology (G.P.),
| | - Gerard Pasterkamp
- From the Molecular Cardiology Laboratory, Experimental Cardiology, Thoraxcenter, Erasmus University Medical Center, Rotterdam, The Netherlands (C.C., D.T., W.K.D.D., R.H., I.C., F.L.B., K.W., E.v.d.K., L.B., P.W.S., H.J.D.); Hubrecht's Institute-KNAW and University Medical Centre, Utrecht, The Netherlands (F.L.B., S.S.-M.); the Department of Pathology, Maastricht University Medical Center, Maastricht, The Netherlands (E.A.L.B.); and the Departments of Vascular Surgery (F.M.) and Cardiology (G.P.),
| | - Patrick W. Serruys
- From the Molecular Cardiology Laboratory, Experimental Cardiology, Thoraxcenter, Erasmus University Medical Center, Rotterdam, The Netherlands (C.C., D.T., W.K.D.D., R.H., I.C., F.L.B., K.W., E.v.d.K., L.B., P.W.S., H.J.D.); Hubrecht's Institute-KNAW and University Medical Centre, Utrecht, The Netherlands (F.L.B., S.S.-M.); the Department of Pathology, Maastricht University Medical Center, Maastricht, The Netherlands (E.A.L.B.); and the Departments of Vascular Surgery (F.M.) and Cardiology (G.P.),
| | - Stefan Schulte-Merker
- From the Molecular Cardiology Laboratory, Experimental Cardiology, Thoraxcenter, Erasmus University Medical Center, Rotterdam, The Netherlands (C.C., D.T., W.K.D.D., R.H., I.C., F.L.B., K.W., E.v.d.K., L.B., P.W.S., H.J.D.); Hubrecht's Institute-KNAW and University Medical Centre, Utrecht, The Netherlands (F.L.B., S.S.-M.); the Department of Pathology, Maastricht University Medical Center, Maastricht, The Netherlands (E.A.L.B.); and the Departments of Vascular Surgery (F.M.) and Cardiology (G.P.),
| | - Henricus J. Duckers
- From the Molecular Cardiology Laboratory, Experimental Cardiology, Thoraxcenter, Erasmus University Medical Center, Rotterdam, The Netherlands (C.C., D.T., W.K.D.D., R.H., I.C., F.L.B., K.W., E.v.d.K., L.B., P.W.S., H.J.D.); Hubrecht's Institute-KNAW and University Medical Centre, Utrecht, The Netherlands (F.L.B., S.S.-M.); the Department of Pathology, Maastricht University Medical Center, Maastricht, The Netherlands (E.A.L.B.); and the Departments of Vascular Surgery (F.M.) and Cardiology (G.P.),
| |
Collapse
|
14
|
Bussmann J, Bos FL, Urasaki A, Kawakami K, Duckers HJ, Schulte-Merker S. Arteries provide essential guidance cues for lymphatic endothelial cells in the zebrafish trunk. Development 2010; 137:2653-7. [DOI: 10.1242/dev.048207] [Citation(s) in RCA: 160] [Impact Index Per Article: 11.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
The endothelial cells of the vertebrate lymphatic system assemble into complex networks, but local cues that guide the migration of this distinct set of cells are currently unknown. As a model for lymphatic patterning, we have studied the simple vascular network of the zebrafish trunk consisting of three types of lymphatic vessels that develop in close connection with the blood vasculature. We have generated transgenic lines that allow us to distinguish between arterial, venous and lymphatic endothelial cells (LECs) within a single zebrafish embryo. We found that LECs migrate exclusively along arteries in a manner that suggests that arterial endothelial cells serve as the LEC migratory substrate. In the absence of intersegmental arteries, LEC migration in the trunk is blocked. Our data therefore demonstrate a crucial role for arteries in LEC guidance.
Collapse
Affiliation(s)
- Jeroen Bussmann
- Hubrecht Institute-KNAW and University Medical Centre, and Centre for Biomedical Genetics, Uppsalalaan 8, 3584 CT Utrecht, the Netherlands
| | - Frank L. Bos
- Hubrecht Institute-KNAW and University Medical Centre, and Centre for Biomedical Genetics, Uppsalalaan 8, 3584 CT Utrecht, the Netherlands
- Molecular Cardiology Laboratory, Experimental Cardiology, Thoraxcenter, Erasmus University Medical Centre Rotterdam, 3015 CE Rotterdam, the Netherlands
| | - Akihiro Urasaki
- Division of Molecular and Developmental Biology, National Institute of Genetics, 1111 Yata, Mishima, Shizuoka 411-8540, Japan
| | - Koichi Kawakami
- Division of Molecular and Developmental Biology, National Institute of Genetics, 1111 Yata, Mishima, Shizuoka 411-8540, Japan
- Department of Genetics, the Graduate University for Advanced Studies (SOKENDAI), 1111 Yata, Mishima, Shizuoka, 411-8540, Japan
| | - Henricus J. Duckers
- Molecular Cardiology Laboratory, Experimental Cardiology, Thoraxcenter, Erasmus University Medical Centre Rotterdam, 3015 CE Rotterdam, the Netherlands
| | - Stefan Schulte-Merker
- Hubrecht Institute-KNAW and University Medical Centre, and Centre for Biomedical Genetics, Uppsalalaan 8, 3584 CT Utrecht, the Netherlands
| |
Collapse
|
15
|
Suijkerbuijk SJE, van Osch MHJ, Bos FL, Hanks S, Rahman N, Kops GJPL. Molecular causes for BUBR1 dysfunction in the human cancer predisposition syndrome mosaic variegated aneuploidy. Cancer Res 2010; 70:4891-900. [PMID: 20516114 DOI: 10.1158/0008-5472.can-09-4319] [Citation(s) in RCA: 84] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Genetic mutations in the mitotic regulatory kinase BUBR1 are associated with the cancer-susceptible disorder mosaic variegated aneuploidy (MVA). In patients with biallelic mutations, a missense mutation pairs with a truncating mutation. Here, we show that cell lines derived from MVA patients with biallelic mutations have an impaired mitotic checkpoint, chromosome alignment defects, and low overall BUBR1 abundance. Ectopic expression of BUBR1 restored mitotic checkpoint activity, proving that BUBR1 dysfunction causes chromosome segregation errors in the patients. Combined analysis of patient cells and functional protein replacement shows that all MVA mutations fall in two distinct classes: those that impose specific defects in checkpoint activity or microtubule attachment and those that lower BUBR1 protein abundance. Low protein abundance is the direct result of the absence of transcripts from truncating mutants combined with high protein turnover of missense mutants. In this group of missense mutants, the amino acid change consistently occurs in or near the BUBR1 kinase domain. Our findings provide a molecular explanation for chromosomal instability in patients with biallelic genetic mutations in BUBR1.
Collapse
Affiliation(s)
- Saskia J E Suijkerbuijk
- Department of Physiological Chemistry and Cancer Genomics Centre, University Medical Center Utrecht, Utrecht, the Netherlands
| | | | | | | | | | | |
Collapse
|